BC Cancer Agency

Factors Associated with Experiences of Navigation and Support Among Indigenous, Black, and Asian Minority Adults Surviving Breast Cancer in British Columbia: Cross-Sectional Study

Social determinants of health, including socioeconomic status, education, employment, and residential location, are fundamental for survival. The aim was to assess the factors associated with experiences of navigation and support among Indigenous, Black and Asian Minority adults...

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in tran...

Federated EGA in the European and Global Human Data Ecosystem

This Federated EGA in the European and Global Human Data Ecosystem white paper sets out our vision for the future role of Federated EGA (FEGA) in supporting secure, responsible and FAIR reuse of controlled-access human data. It describes how FEGA has developed into an operational...

Ensemble clustering: A practical tutorial

Abstract Cluster analysis is an explorative analytical method, serving as a critical tool in psychology, psychiatry, and related fields to map heterogeneous data into meaningful subgroups. Despite their extensive historical use, traditional clustering techniques suffer from a lac...

miR-142-3p in cancer: intracellular tumor suppression and extracellular vesicle- mediated microenvironmental signaling

miR-142-3p has emerged as an important regulator of cancer progression and treatment response, exhibiting predominantly tumor-suppressive functions. Intracellularly, miR-142-3p inhibits proliferation, promotes apoptosis, suppresses epithelial–mesenchymal transition (EMT), and enh...

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...

Towards clinical implementation of artificial intelligence in cancer care: concept mapping analysis of provincial workshop findings

Abstract Background Artificial intelligence (AI) has rapidly garnered interest in healthcare. Cancer care’s multidisciplinary nature and high coordination demands are well positioned to benefit from AI. While attitudes toward implementation of AI in medicine have been explored ge...